---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-033929"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:25:44.749190+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Puma Biotech Q3 net income $20.3M vs $5.8M YoY; raises FY 2024 guidance

## Summary
- Product revenue $56.1M (+8.7% YoY); total revenue $80.5M including $24.4M royalty revenue.
- GAAP EPS $0.41 diluted; adjusted non-GAAP EPS $0.45 diluted.
- FY 2024 net product revenue guidance raised to $187-190M (from $183-190M); net income raised to $15-17M.
- Cash & securities $97M at Sept 30; operating cash flow $11M in Q3.
- Phase II alisertib trials in SCLC and breast cancer on track; interim data expected in 2025.

## SEC filing metadata
- accession: 0001437749-24-033929
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000143774924033929/0001437749-24-033929-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000143774924033929/pbyi20241106_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-033929
- JSON: https://secwatch.observer/filing/0001437749-24-033929.json
- Plain text: https://secwatch.observer/filing/0001437749-24-033929.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.